CN1314909A - 具有抗HIV活性的d4T的磷酸芳基酯衍生物 - Google Patents

具有抗HIV活性的d4T的磷酸芳基酯衍生物 Download PDF

Info

Publication number
CN1314909A
CN1314909A CN99810072A CN99810072A CN1314909A CN 1314909 A CN1314909 A CN 1314909A CN 99810072 A CN99810072 A CN 99810072A CN 99810072 A CN99810072 A CN 99810072A CN 1314909 A CN1314909 A CN 1314909A
Authority
CN
China
Prior art keywords
compound
composition
hiv
group
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99810072A
Other languages
English (en)
Chinese (zh)
Inventor
F·M·乌昆
R·维格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parker Hughes Institute
Original Assignee
Parker Hughes Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Institute filed Critical Parker Hughes Institute
Publication of CN1314909A publication Critical patent/CN1314909A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN99810072A 1998-06-29 1999-06-29 具有抗HIV活性的d4T的磷酸芳基酯衍生物 Pending CN1314909A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/107,716 US6030957A (en) 1998-06-29 1998-06-29 Aryl phosphate derivatives of d4T having anti-HIV activity
US09/107716 1998-06-30

Publications (1)

Publication Number Publication Date
CN1314909A true CN1314909A (zh) 2001-09-26

Family

ID=22318071

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99810072A Pending CN1314909A (zh) 1998-06-29 1999-06-29 具有抗HIV活性的d4T的磷酸芳基酯衍生物

Country Status (14)

Country Link
US (7) US6030957A (enExample)
EP (1) EP1090018B1 (enExample)
JP (1) JP2002519355A (enExample)
KR (1) KR20010071673A (enExample)
CN (1) CN1314909A (enExample)
AT (1) ATE277940T1 (enExample)
AU (1) AU4846999A (enExample)
BR (1) BR9911685A (enExample)
CA (1) CA2336285A1 (enExample)
DE (1) DE69920696T2 (enExample)
HU (1) HUP0102527A3 (enExample)
IL (1) IL140388A0 (enExample)
NO (1) NO20006685L (enExample)
WO (1) WO2000000501A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103403014A (zh) * 2011-01-03 2013-11-20 南京迈勒克生物技术研究中心 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030957A (en) * 1998-06-29 2000-02-29 Wayne Hughes Institute Aryl phosphate derivatives of d4T having anti-HIV activity
US20070015733A1 (en) * 1998-06-29 2007-01-18 Parker Hughes Institute Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains
US7144874B2 (en) * 2002-10-25 2006-12-05 Parker Hughes Institute Aryl phosphate derivatives of d4T having activity against resistant HIV strains
WO2000056750A1 (en) * 1999-03-19 2000-09-28 Parker Hughes Institute One pot synthesis of 5'-hydroxy phosphorylated nucleoside derivatives, and compounds formed thereby
US6825177B2 (en) * 2000-10-30 2004-11-30 Parker Hughes Institute Aryl phosphate derivatives of d4T with potent anti-viral activity
ATE297940T1 (de) * 2000-11-13 2005-07-15 Parker Hughes Inst Arylphosphatderivate von d4t
AU2003239901A1 (en) * 2002-05-28 2003-12-12 Kathy M. Ensrud Crisp polypeptides as contraceptives and inhibitors of sperm capacitation
US20030236218A1 (en) * 2002-06-12 2003-12-25 Uckun Fatih M. Aryl phosphate derivatives of d4T with selective activity against adenovirus and HIV
US20040076931A1 (en) * 2002-10-18 2004-04-22 Cashflow Technologies, Inc. Educational interactive games
US20040077607A1 (en) * 2002-10-21 2004-04-22 Uckun Fatih M. Aryl phosphate derivatives of d4T with potent anti-viral activity against hemorrhagic fever viruses
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
EP1773355B1 (en) * 2004-06-24 2014-06-25 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2006026656A1 (en) * 2004-08-31 2006-03-09 Parker Hughes Institute Cytotoxic nucleoside analog compound 003 for treating cancer
EP1827460A4 (en) * 2004-12-09 2012-03-14 Univ Minnesota NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
US10618013B2 (en) * 2005-03-09 2020-04-14 The Regents Of The University Of California Nanocomposite membranes and methods of making and using same
US7892618B2 (en) * 2005-03-21 2011-02-22 Sony Corporation Deterring theft of optical media
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
EP2623104A1 (en) * 2009-03-20 2013-08-07 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
CA2810928A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
CN105705511A (zh) 2013-04-12 2016-06-22 艾其林医药公司 用于治疗hcv的氘化核苷前药

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707362A (en) 1985-02-15 1987-11-17 Biotek, Inc. Sustained release composition
US4841039A (en) 1986-05-01 1989-06-20 Emory University 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
JPH06189998A (ja) 1992-11-06 1994-07-12 C & Co:Yugen コンド―ム
CA2130265A1 (en) 1992-12-18 1994-07-07 Edward E. Knaus Dihydropyrimidine nucleosides with antiviral properties
ZA947572B (en) 1993-09-29 1995-09-28 Hampton Roads Medical College Contraceptive compositions
US5672698A (en) * 1993-11-15 1997-09-30 Bristol-Myers Squibb Co. Preparation of 2',3'-didehydro-3'-deoxythymidine from 5-methyluridine
US5659023A (en) * 1995-02-01 1997-08-19 Gilead Sciences, Inc. Nucleotide analogues
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
IL126804A0 (en) 1996-05-09 1999-08-17 Bergeron Michel G Formulation for use in the prevention of pathogen induced diseases including hiv and hsv
US6030957A (en) 1998-06-29 2000-02-29 Wayne Hughes Institute Aryl phosphate derivatives of d4T having anti-HIV activity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103403014A (zh) * 2011-01-03 2013-11-20 南京迈勒克生物技术研究中心 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
CN103403014B (zh) * 2011-01-03 2016-07-06 河南美泰宝生物制药有限公司 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途

Also Published As

Publication number Publication date
HUP0102527A3 (en) 2002-04-29
US6030957A (en) 2000-02-29
AU4846999A (en) 2000-01-17
EP1090018A1 (en) 2001-04-11
BR9911685A (pt) 2001-12-18
ATE277940T1 (de) 2004-10-15
US6350736B1 (en) 2002-02-26
EP1090018B1 (en) 2004-09-29
US7071176B2 (en) 2006-07-04
HUP0102527A2 (hu) 2001-12-28
JP2002519355A (ja) 2002-07-02
US6503890B1 (en) 2003-01-07
NO20006685D0 (no) 2000-12-28
DE69920696D1 (de) 2004-11-04
NO20006685L (no) 2001-02-28
KR20010071673A (ko) 2001-07-31
US6528495B1 (en) 2003-03-04
CA2336285A1 (en) 2000-01-06
US6670336B1 (en) 2003-12-30
WO2000000501A1 (en) 2000-01-06
IL140388A0 (en) 2002-02-10
US6537975B1 (en) 2003-03-25
US20040171577A1 (en) 2004-09-02
DE69920696T2 (de) 2006-03-02

Similar Documents

Publication Publication Date Title
CN1314909A (zh) 具有抗HIV活性的d4T的磷酸芳基酯衍生物
CN100343268C (zh) β-2′-或3′-卤代核苷
CN103403014B (zh) O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
Nair et al. Antiviral activities of isometric dideoxynucleosides of D-and L-related stereochemistry
US8895531B2 (en) 2′-fluoronucleoside phosphonates as antiviral agents
McIntee et al. Probing the mechanism of action and decomposition of amino acid phosphomonoester amidates of antiviral nucleoside prodrugs
US20140212382A1 (en) Purine monophosphate prodrugs for treatment of viral infections
JP2005503358A5 (enExample)
WO2017197377A1 (en) Peptidomimetics for the treatment of norovirus infection
JPH0780898B2 (ja) 抗ウイルスヌクレオシド
WO2003051306A2 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
Zhou et al. 2′-Chloro, 2′-fluoro ribonucleotide prodrugs with potent pan-genotypic activity against hepatitis C virus replication in culture
Meier et al. C yclo Sal-BVDUMP Pronucleotides: How to Convert an Antiviral-Inactive Nucleoside Analogue into a Bioactive Compound against EBV
Krecmerova et al. Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy) propyl]-2, 6-diaminopurine (HPMPDAP) as anti-poxvirus agents
Kim et al. Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro
WO2006017052A1 (en) Process for the preparation of a1 adenosine receptor agonists
US11618765B2 (en) Broad-spectrum antiviral nucleoside derivatives
Koszalka et al. Advances in Nucleoside and Nucleotide Antiviral Therapies
Bryant et al. Antiviral β-L-nucleosides specific for hepatitis B virus infection
Ducho et al. Novel cycloSal nucleotides with reduced inhibitory potency toward human butyrylcholinesterase
HK1195317A (en) Purine monophosphate prodrugs for treatment of viral infections
HK1076473B (en) β-2'-OR 3'-HALONUCLEOSIDES
MXPA00013013A (en) ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ANTI-HIV ACTIVITY

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication